CLINICAL_TRIALS
research
· 2026-04-20
Clinical Trial Update: Testing the SurVaxM Vaccine for Lung Cancer Prevention [Phase 2]
Summary
A Phase 2 clinical trial is evaluating the SurVaxM cancer vaccine for lung cancer prevention, with recruitment not yet started.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: National Cancer Institute (NCI) | Conditions: Lung Carcinoma | Phase 2 | Status: NOT_YET_RECRUITING